Carbohydrate-based whole cell cancer vaccines
CA 2399325 A1 · Owner: National Research Council Of Canada · Inventors: Liu, Tianmin; Yang, Qingling; Jennings, Harold J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
When tumor cells are incubated with N-propionyl mannosamine the N-acetyl, groups of their surface .alpha.2-8 polysialic acid are converted to Npropionyl groups. The, resultant bio-engineered cancer cells can be killed and used as a allogenic or autologous, therapy or vaccine. The presence of N-propionylated polysialic acid-specific antibodies is, detected in animals immunized with the vaccine prior to tumor implantation. Mice, immunized with the heat-killed cancer cells experience better protection against challenge, with live autologous RMA-S cells than mice immunized with heat-killed autologous, RMA-S cells. Killed cells having modified sialic acid groups on their surface may be …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 21, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 21, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 21, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.